REIT-backed Hospital Deals Accelerate
Now that hospitals and health systems have realized most of the benefits they expected from the Affordable Care Act, the mergers and acquisitions in the hospital sector have been supplanted by partnerships, clinical collaborations, joint ventures, strategic alliances and affiliations. But there is one group of acquirers still on the prowl: real estate investment trusts (REITs). Their interest and investment in this sector has grown since 2014, when only three REIT-sponsored deals were announced. Those deals targeted one hospital each, with a total of 94 beds. Combined spending was $1.27 billion. The action picked up in 2015, with six REIT-backed deals announced. The largest was made by... Read More »WellCare Branches into Arizona with Care1st Buy
WellCare Health Plans, Inc. (NYSE: WCG) is moving into the Arizona Medicare and Medicaid markets. Care1st Health Plan, an affiliate of Blue Shield of California, agreed to sell its subsidiaries Care1st Health Plan Arizona, Inc. and ONECare by Care1st Health Plan of Arizona, Inc. (together, Care1st Arizona), managed care companies that provide Medicaid and Medicare benefits to approximately 114,ooo beneficiaries in Maricopa and Pima counties, Arizona’s largest geographic service areas. The $157.5 million purchase price is inclusive of statutory capital and subject to certain adjustments, and will be funded with available cash on hand. WellCare provides government-sponsored managed... Read More »AstraZeneca Sheds Assets After its Trial Failure
AstraZeneca (NYSE: AZN) has been on the receiving end of three different purchases in the first five days of October, selling licenses to three of its non-core assets for a combined upfront payment of $450 million. Its selling spree occurred in tandem with the announced trial failure of its blood thinner Brilinta (ticagrelor), which failed to show any benefit over the standard medication for the treatment of peripheral artery disease (PAD). According to Reuters, the trial failure forced the company to abandon a $3.5 billion-a-year sales target for the drug by 2023. On October 3rd, AstraZeneca’s biologics arm, MedImmune, agreed to license the worldwide rights to Allergan plc (NYSE:... Read More »Pfizer Sells Hospira’s Infusion Therapy Business
Way back in February 2015, Pfizer Inc. (NYSE: PFE) agreed to pay $17 billion to acquire Hospira, Inc., a global provider of injectable drugs and infusion technologies. In early October 2016, Pfizer agreed to sell Hospira’s infusion therapy business to ICU Medical Inc. (NASDAQ: ICUI) for $1 billion in cash and stock. The company develops, manufactures and sells medical devices used in infusion therapy, oncology and critical care applications. Pfizer will receive approximately $400 million in newly issued shares of ICU Medical common stock and $600 million in cash from ICU, for a total purchase price of approximately $1 billion. Upon completion, Pfizer will own approximately 16.6% of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
